H1 2026 saw 2.7% organic revenue growth, 130bps adjusted EBITDA margin expansion, and 29% EPS growth, with strong cash conversion and profitability nearing 2027 targets. Strategic portfolio moves included the divestment of MET Labs and the acquisition of Element's Life Sciences Testing Services.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.